The LEAD COVID-19 Trial: Low-risk, Early Aspirin and Vitamin D to Reduce COVID-19 Hospitalizations

NCT04363840 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped lack of funding

Conditions

COVID
Vitamin D Deficiency
Coagulopathy
Disseminated Intravascular Coagulation

Interventions

DRUG: Aspirin 81 mg
DIETARY_SUPPLEMENT: Vitamin D

Sponsor

Louisiana State University Health Sciences Center in New Orleans